Background Many studies reported high prevalence of antiphospholipid antibodies (aPL) in
patients with COVID-19 raising questions about its true prevalence and its clinical impact on …

1Oxford Haemophilia and Thrombosis Centre, Churchill Hospital, Oxford, UK, 2Haemostasis
Research Unit, Haematology Department, University College London, London, UK, 3Centre …

Antiphospholipid antibodies (aPL) are both diagnostic markers for, and pathogenic drivers
of, antiphospholipid syndrome (APS). Although the presence of aPL is a necessary pre …

The antiphospholipid syndrome (APS) is defined by the presence of thrombosis and/or
pregnancy morbidity in combination with the persistent presence of circulating …

Platelets contribute to processes beyond thrombus formation and may play a so far
underestimated role as an immune cell in various circumstances. This review outlines …

Antiphospholipid syndrome (APS), an acquired autoimmune thrombophilia, is characterised
by thrombosis and/or pregnancy morbidity in association with persistent antiphospholipid …

Antiphospholipid Syndrome (APS) is characterized by vascular thrombosis and/or
pregnancy morbidity occurring in patients with persistent antiphospholipid antibodies (aPL) …

Platelets participate in a variety of responses of the blood to injury. An emerging body of
evidence suggests that these cells express an intrinsic capacity to interact with and trigger …

BACKGROUND: Anti-β2GP1 (β2-glycoprotein 1) antibodies are the primary pathogenic
antibody to promote thrombosis in antiphospholipid syndrome (APS), yet the underlying …

OBJECTIVES. The purpose of this study was to obtain data on the association of
antiphospholipid antibodies with clinical manifestations in childhood and to enable future …